ATARA BIOTHERAPEUTICS INC (ATRA) Stock Price, Quote, News and Overview
NASDAQ:ATRA - Nasdaq - US0465132068 - Common Stock - Currency: USD
ATRA Quote, Performance and Key Statistics
NASDAQ:ATRA (5/9/2025, 8:00:01 PM)
7.27
-0.15 (-2.02%)
The current stock price of ATRA is 7.27 USD. In the past month the price increased by 37.17%. In the past year, price decreased by -45.12%.
ATRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.97 | 326.55B | ||
| AMGN | AMGEN INC | 12.81 | 142.94B | ||
| GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
| ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
| ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
| BIIB | BIOGEN INC | 7.47 | 17.32B |
Related stock screener links
About ATRA
Company Profile
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California and currently employs 153 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Company Info
ATARA BIOTHERAPEUTICS INC
1280 Rancho Conejo Blvd
Thousand Oaks CALIFORNIA 94080 US
CEO: Pascal Touchon
Employees: 153
Phone: 18056234211
ATARA BIOTHERAPEUTICS INC / ATRA FAQ
What is the stock price of ATARA BIOTHERAPEUTICS INC today?
The current stock price of ATRA is 7.27 USD. The price decreased by -2.02% in the last trading session.
What is the ticker symbol for ATARA BIOTHERAPEUTICS INC stock?
The exchange symbol of ATARA BIOTHERAPEUTICS INC is ATRA and it is listed on the Nasdaq exchange.
On which exchange is ATRA stock listed?
ATRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ATARA BIOTHERAPEUTICS INC stock?
11 analysts have analysed ATRA and the average price target is 15.64 USD. This implies a price increase of 115.13% is expected in the next year compared to the current price of 7.27. Check the ATARA BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATARA BIOTHERAPEUTICS INC worth?
ATARA BIOTHERAPEUTICS INC (ATRA) has a market capitalization of 43.33M USD. This makes ATRA a Nano Cap stock.
How many employees does ATARA BIOTHERAPEUTICS INC have?
ATARA BIOTHERAPEUTICS INC (ATRA) currently has 153 employees.
What are the support and resistance levels for ATARA BIOTHERAPEUTICS INC (ATRA) stock?
ATARA BIOTHERAPEUTICS INC (ATRA) has a support level at 7.26 and a resistance level at 7.68. Check the full technical report for a detailed analysis of ATRA support and resistance levels.
Is ATARA BIOTHERAPEUTICS INC (ATRA) expected to grow?
The Revenue of ATARA BIOTHERAPEUTICS INC (ATRA) is expected to decline by -70.2% in the next year. Check the estimates tab for more information on the ATRA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ATARA BIOTHERAPEUTICS INC (ATRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATRA, evaluating the profitability, health, valuation and growth aspects
- ATARA BIOTHERAPEUTICS INC (ATRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATARA BIOTHERAPEUTICS INC (ATRA) Sales and EPS estimates to see what analysts future expectations are.
- ATARA BIOTHERAPEUTICS INC (ATRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATARA BIOTHERAPEUTICS INC (ATRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATARA BIOTHERAPEUTICS INC (ATRA) Stock Chart to make your own analysis
- ATARA BIOTHERAPEUTICS INC (ATRA) Latest news and press-releases to stay up to date.
Does ATARA BIOTHERAPEUTICS INC (ATRA) stock pay dividends?
ATRA does not pay a dividend.
When does ATARA BIOTHERAPEUTICS INC (ATRA) report earnings?
ATARA BIOTHERAPEUTICS INC (ATRA) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of ATARA BIOTHERAPEUTICS INC (ATRA)?
ATARA BIOTHERAPEUTICS INC (ATRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.97).
What is the Short Interest ratio of ATARA BIOTHERAPEUTICS INC (ATRA) stock?
The outstanding short interest for ATARA BIOTHERAPEUTICS INC (ATRA) is 14.65% of its float. Check the ownership tab for more information on the ATRA short interest.
ATRA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ATRA. When comparing the yearly performance of all stocks, ATRA is a bad performer in the overall market: 88.53% of all stocks are doing better.
ATRA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ATRA. ATRA may be in some trouble as it scores bad on both profitability and health.
ATRA Financial Highlights
Over the last trailing twelve months ATRA reported a non-GAAP Earnings per Share(EPS) of -12.97. The EPS increased by 80.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.28% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ATRA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ATRA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 60.52% and a revenue growth -70.2% for ATRA